Blog

Ipilimumab +Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma
Condition:   Soft Tissue Sarcoma
Interventions:   Drug: Ipilimumab;   Procedure: Cryoablation;   Drug: Nivolumab
Sponsors:   Stanford University;   Bristol-Myers Squibb
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 22, 2019 / by / in
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Conditions:   Melanoma;   Breast Carcinoma;   Hepatocellular Carcinoma;   Urothelial Carcinoma;   Squamous Cell Carcinoma of the Head and Neck;   Renal Cell Carcinoma;   Colorectal Carcinoma;   Non-small Cell Lung Carcinoma;   Gastric or Gastroesophageal Junction Adenocarcinoma;   Endometrial Carcinoma;   Mesothelioma;   Neuroendocrine Carcinoma;   Cervical Cancer;   Small Cell Lung Carcinoma;   Squamous Cell Carcinoma of the Anus
Intervention:   Biological: XmAb20717
Sponsors:   Xencor, Inc.;   ICON plc
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 18, 2019 / by / in
The Gastric Cancer Foundation: A Gastric Cancer Registry
Condition:   Gastric Cancer
Intervention:  
Sponsor:   Stanford University
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 18, 2019 / by / in
Phase 1 Study to Determine the MTD, Safety, Tolerability, PK and Preliminary Anti-tumor Effects of LNS8801
Conditions:   Solid Tumor, Adult;   Lymphoma
Intervention:   Drug: Small molecule, orally bioavailable, selective agonist of GPER
Sponsor:   Linnaeus Therapeutics, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 18, 2019 / by / in
A Pilot Study of BXCL701 in Patients With Pancreatic Cancer
Conditions:   Cancer of Pancreas;   Cancer of the Pancreas;   Neoplasms, Pancreatic;   Pancreas Cancer;   Pancreatic Cancer
Intervention:   Drug: Talabostat Mesylate
Sponsors:   BioXcel Therapeutics Inc;   IQVIA Biotech
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 18, 2019 / by / in
Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
Conditions:   Gastroparesis;   Dyspepsia
Interventions:   Drug: Cannabidiol;   Other: placebo
Sponsor:   Mayo Clinic
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 17, 2019 / by / in
Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia
Conditions:   Aml;   AML, Adult
Interventions:   Drug: Nivolumab;   Drug: Azacitidine
Sponsor:   Sherif Farag
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 17, 2019 / by / in
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer
Condition:   Breast Cancer
Interventions:   Drug: Tamoxifen Citrate;   Drug: Letrozole;   Drug: Exemestane;   Diagnostic Test: Blueprint;   Diagnostic Test: Mammaprint
Sponsors:   Johns Hopkins University;   Agendia
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 17, 2019 / by / in
Study of AMV564 in Subjects With Advanced Solid Tumors
Condition:   Locally Advanced or Metastatic Solid Tumors
Intervention:   Biological: AMV564
Sponsor:   Amphivena Therapeutics, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 17, 2019 / by / in
A Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment With Ibrutinib
Condition:   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Intervention:   Drug: Zanubrutinib
Sponsor:   BeiGene
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 17, 2019 / by / in